 |
25 Diseases |  |
0 Trials |
|
0 Trials |  |
4 News |  |
- | StemEx (carlecortemcel-L) / Gamida Cell
Journal: Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. (Pubmed Central) - Jun 15, 2019
P2/3
In this multi-national comparative study, transplanting expanded CD34+ stem cells from a portion of a single UCB unit, with the remaining un-manipulated fraction improved 100 day survival compared to DUCBT controls while facilitating myeloid and platelet engraftment. This trial was registered at www.clinicaltrials.gov as #NCT00469729.
- | StemEx (carlecortemcel-L) / Gamida Cell
Trial completion, Trial primary completion date: ExCell: Efficacy and Safety Study of StemEx (clinicaltrials.gov) - Jul 10, 2015
P2/3, N=101, Completed, Sponsor: Gamida Cell -Teva Joint Venture Ltd.
This trial was registered at www.clinicaltrials.gov as #NCT00469729. Active, not recruiting --> Completed | Trial primary completion date: Jul 2013 --> Feb 2013
- | StemEx (carlecortemcel-L) / Gamida Cell
Enrollment closed: ExCell: Efficacy and Safety Study of StemEx (clinicaltrials.gov) - Feb 14, 2012
P2/3, N=100, Active, not recruiting, Sponsor: Gamida Cell -Teva Joint Venture Ltd.
Active, not recruiting --> Completed | Trial primary completion date: Jul 2013 --> Feb 2013 Recruiting --> Active, not recruiting